SER Stock Analysis
SE
Uncovered
Serina Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Serina Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Alameda, California and currently employs 4 full-time employees. The company went IPO on 2018-11-29. Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The firm is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The firm is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The firm intends to advance SER 252 into Phase I clinical trials.